NCT07334574 — Ruijin Hospital cancer vaccine trial
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
Registry record
| Registry ID | NCT07334574 ↗ |
|---|---|
| Lead sponsor | Ruijin Hospital |
| Collaborators | Shanghai Xinpu BioTechnology Company Limited |
| Phase | Phase 1 |
| Status | Not Yet Recruiting |
| Indication | B-cell Non-Hodgkin's Lymphoma (B-NHL) |
| Enrollment | 20 participants (target) |
| Start date | 2026-01-15 |
| Primary completion | 2028-01-01 (est.) |
| Last registry update | 13 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07334574), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07334574?
NCT07334574 (Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL) is registered on ClinicalTrials.gov as Phase 1, sponsored by Ruijin Hospital.
Is NCT07334574 recruiting?
As of the 2026-01-13 registry update, NCT07334574 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07334574?
The lead sponsor is Ruijin Hospital. Collaborators: Shanghai Xinpu BioTechnology Company Limited.
What condition does NCT07334574 study?
The registered condition is B-cell Non-Hodgkin's Lymphoma (B-NHL). Primary completion is listed as 2028-01-01 (estimated).
Are results available for NCT07334574?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07334574.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.